HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on ADMA Biologics and increased the price target from $7.5 to $10.
May 10, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The Buy rating reaffirmation and price target increase to $10 from $7.5 by HC Wainwright & Co. for ADMA Biologics signals strong analyst confidence in the company's future performance.
Analyst ratings and price target adjustments are significant indicators of a stock's potential future performance. The increase in ADMA Biologics' price target by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on the company's value and potential for growth, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100